Clinical Trial: NCT03391466
Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma
Status:
COMPLETEDPhase:
Phase 3| Lead Sponsor: | Kite, A Gilead Company |
| Information Provided By: | Gilead Sciences |
| Last Update Posted: | 2025-12-01 |
Study Overview
Brief Summary
The goal of this clinical study is to assess whether axicabtagene ciloleucel therapy improves the clinical outcome compared with standard of care second-line therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Official Title
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
Conditions
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Intervention / Treatment
- Biological: Axicabtagene Ciloleucel
- Drug: Platinum-containing Salvage Chemotherapy
- Drug: Cyclophosphamide
- Drug: Fludarabine
Other Study ID Numbers
- KTE-C19-107
- 2017-002261-22
- 2017
Start Date (Actual)
2018-01-25
Primary Completion Date (Actual)
2021-03-18
Study Completion Date (Actual)
2024-11-25
Enrollment (Actual)
359
Study Type
Interventional
Phase
Phase 3
| Lead Sponsor: | Kite, A Gilead Company |
| Information Provided By: | Gilead Sciences |
| Last Update Posted: | 2025-12-01 |
Study Overview
Brief Summary
The goal of this clinical study is to assess whether axicabtagene ciloleucel therapy improves the clinical outcome compared with standard of care second-line therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Official Title
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
Conditions
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Intervention / Treatment
- Biological: Axicabtagene Ciloleucel
- Drug: Platinum-containing Salvage Chemotherapy
- Drug: Cyclophosphamide
- Drug: Fludarabine
Other Study ID Numbers
- KTE-C19-107
- 2017-002261-22
- 2017
Start Date (Actual)
2018-01-25
Primary Completion Date (Actual)
2021-03-18
Study Completion Date (Actual)
2024-11-25
Enrollment (Actual)
359
Study Type
Interventional
Phase
Phase 3